NRG GY009

Primary Category:

Treatment Protocols

Disease Category:

Gynecologic, Ovarian, Ovarian Metastatic

Status:

Temporarily Closed

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer

NCT#02839707

NRG-GY009 has met its Phase II accrual goal and is temporarily closed effective May 9th, 2019.